Business Wire

CO-WESTERN-UNION

29.6.2022 14:02:05 CEST | Business Wire | Press release

Share
Western Union Highlights ESG Progress and Recognitions Received

The Western Union Company (NYSE: WU) today released its 2021 Environmental, Social and Governance (ESG) Report, spotlighting the Company’s ongoing commitment to advancing its strategy and actions aligned with key ESG priorities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005138/en/

“People are drawn to work for and do business with companies that make an impact,” said Devin McGranahan, Chief Executive Officer. “This year’s report shows that Western Union continues to make solid progress on our ESG journey, which in turn enables us to effect even more positive change in the communities we serve. I’m proud to work with colleagues who bring their best every day to improve the lives of our customers and communities around the world.”

2021 ESG Highlights

Western Union’s ESG strategy is focused on efforts and areas where the Company can make meaningful impact, including:

  • Furthering economic prosperity: The Company launched a digital banking platform in Germany and Romania, combining money transfer, a multi-currency account and debit card. Western Union believes offering people simple, trusted solutions via digital and retail access points creates pathways for long-term economic success.
  • Promoting the integrity of money movement: Western Union also continued progress on our commitment to money movement that is safe, secure and built on a foundation of integrity. While third-party data show the rate of fraudulent activity across the financial industry is increasing, in 2021 our Company’s reported consumer fraud globally decreased by 10% and we prevented approximately $1.9 billion in fraudulent transactions. These efforts were supported by fraud prevention messages that reached consumers through 121 million consumer fraud touches, a 97% increase over 2020.1
  • Advancing diversity, equity, and inclusion: Another key area of focus for the Company in 2021 was advancing diversity, equity and inclusion (DEI). In 2021, Western Union developed a DEI strategy focused on hiring, development, promotion, retention and cultural change. DEI milestones include:
    • A newly formed DEI program office, naming a Chief Diversity and Talent Officer, a specialized diversity recruiting lead and a full-time DEI program lead; and
    • Achieving gender pay equity globally and racial/ethnicity pay equity in the US.

This year also marks the first time Western Union has disclosed our Company’s Scope 1 and 2 greenhouse gas (GHG) emissions.

Increased Recognition

The Company also reported recognitions for its ESG efforts, including:

  • Recognized as one of the World’s Most Ethical Companies® for the first time;
  • Bloomberg’s Gender Equality Index for the third consecutive year;
  • JUST Capital’s Top 100 Companies Supporting Healthy Families and Communities; and
  • Human Rights Campaign’s Best Place to Work for LGBTQ+ Equality.

For more information and additional details related to our 2021 progress, and to download Western Union’s 2021 Environmental, Social and Governance (ESG) Report, click here .

About Western Union

The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement and payments. Western Union’s platform provides seamless cross-border flows and its leading global financial network bridges more than 200 countries and territories and over 130 currencies. We connect consumers, businesses, financial institutions, and governments through one of the world’s widest reaching networks, accessing billions of bank accounts, millions of digital wallets and cards, and a substantial global network of retail locations. Western Union connects the world to bring boundless possibilities within reach. For more information, visit www.westernunion.com .

________________________________

1. Consumer Fraud Awareness Touches are derived from metrics tracked across various platforms, including paid media ads, social media (Facebook, Twitter, YouTube, Community Management), outreach attendees and wu.com/fraudawareness visits. Each platform may have a unique method for quantifying individuals who have consumed anti-fraud content, based on reach, impressions, views, visits and/ or received physical materials. Given that consumers may engage with our content through multiple channels, each “touch” may not be a unique consumer.

WU-G

Link:

ClickThru

Social Media:

https://www.facebook.com/westernunion

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye